Trial Profile
A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled, Safety Study of Pimavanserin Therapy in Adult and Elderly Subjects Experiencing Neuropsychiatric Symptoms Related to Neurodegenerative Disease
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Pimavanserin (Primary)
- Indications Alzheimer's disease; Corticobasal degeneration; Dementia; Lewy body disease; Neurodegenerative disorders; Parkinson's disease; Progressive supranuclear palsy; Vascular dementia
- Focus Adverse reactions; Registrational
- Sponsors Acadia Pharmaceuticals
- 20 Jul 2023 Results assessing safety profile of pimavanserin therapy in elderly patients with neurodegenerative disease-related neuropsychiatric symptoms presented at the Alzheimer's Association International Conference 2023
- 06 Jun 2022 Status changed from active, no longer recruiting to completed.
- 06 May 2022 This trial has been completed in Czechia, according to European Clinical Trials Database record.